Terms: = Sarcomas AND AXIN2, AXIL, 8313, ENSG00000168646, MGC126582, DKFZp781B0869
19 results:
1. RHAMM/hyaluronan inhibit β-catenin degradation, enhance downstream signaling, and facilitate fibrosarcoma cell growth.
Berdiaki A; Thrapsanioti LN; Giatagana EM; K Karamanos N; C Savani R; N Tzanakakis G; Nikitovic D
Mol Biol Rep; 2023 Nov; 50(11):8937-8947. PubMed ID: 37710072
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological analysis and genomic profiling of a rare histiocyte-rich rhabdomyoblastic tumor: A case report.
Xia Y; Li Y; Gong P; Jiang H; Zhang X
Medicine (Baltimore); 2021 Jun; 100(24):e26105. PubMed ID: 34128847
[TBL] [Abstract] [Full Text] [Related]
3. The effect of baicalein on Wnt/β-catenin pathway and miR-25 expression in Saos-2 osteosarcoma cell line.
Örenlili Yaylagül E; Ülger C
Turk J Med Sci; 2020 Jun; 50(44):1168-1179. PubMed ID: 32283909
[TBL] [Abstract] [Full Text] [Related]
4.
Li S; Wu X; Pei Y; Wang W; Zheng K; Qiu E; Zhang X
DNA Cell Biol; 2019 Nov; 38(11):1323-1337. PubMed ID: 31536386
[TBL] [Abstract] [Full Text] [Related]
5. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.
Tian H; Zhou T; Chen H; Li C; Jiang Z; Lao L; Kahn SA; Duarte MEL; Zhao J; Daubs MD; Buser Z; Brochmann EJ; Wang JC; Murray SS
J Orthop Res; 2019 Jul; 37(7):1638-1648. PubMed ID: 30737824
[TBL] [Abstract] [Full Text] [Related]
6. Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.
Zeng S; Seifert AM; Zhang JQ; Cavnar MJ; Kim TS; Balachandran VP; Santamaria-Barria JA; Cohen NA; Beckman MJ; Medina BD; Rossi F; Crawley MH; Loo JK; Maltbaek JH; Besmer P; Antonescu CR; DeMatteo RP
Mol Cancer Ther; 2017 Sep; 16(9):1954-1966. PubMed ID: 28611108
[TBL] [Abstract] [Full Text] [Related]
7. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract] [Full Text] [Related]
8. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
[TBL] [Abstract] [Full Text] [Related]
9. NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition.
Madan B; Ke Z; Lei ZD; Oliver FA; Oshima M; Lee MA; Rozen S; Virshup DM
Oncotarget; 2016 Mar; 7(11):12386-92. PubMed ID: 26848981
[TBL] [Abstract] [Full Text] [Related]
10. AHSA1 regulates proliferation, apoptosis, migration, and invasion of osteosarcoma.
Shao J; Wang L; Zhong C; Qi R; Li Y
Biomed Pharmacother; 2016 Feb; 77():45-51. PubMed ID: 26796264
[TBL] [Abstract] [Full Text] [Related]
11. MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting axin2.
Lu T; Zhang C; Chai MX; An YB; Jia JL
Int J Clin Exp Pathol; 2015; 8(9):10776-83. PubMed ID: 26617789
[TBL] [Abstract] [Full Text] [Related]
12. Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.
Martins-Neves SR; Corver WE; Paiva-Oliveira DI; van den Akker BE; Briaire-de-Bruijn IH; Bovée JV; Gomes CM; Cleton-Jansen AM
J Cell Physiol; 2016 Apr; 231(4):876-86. PubMed ID: 26332365
[TBL] [Abstract] [Full Text] [Related]
13. Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.
Scholten DJ; Timmer CM; Peacock JD; Pelle DW; Williams BO; Steensma MR
PLoS One; 2014; 9(10):e111431. PubMed ID: 25347326
[TBL] [Abstract] [Full Text] [Related]
14. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.
Stratford EW; Daffinrud J; Munthe E; Castro R; Waaler J; Krauss S; Myklebost O
Cancer Med; 2014 Feb; 3(1):36-46. PubMed ID: 24403055
[TBL] [Abstract] [Full Text] [Related]
15. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract] [Full Text] [Related]
16. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer.
Yang GB; Barnholtz-Sloan JS; Chen Y; Bordeaux JS
Arch Dermatol; 2011 Dec; 147(12):1395-402. PubMed ID: 22184761
[TBL] [Abstract] [Full Text] [Related]
17. Wnt10b activates the Wnt, notch, and NFκB pathways in U2OS osteosarcoma cells.
Mödder UI; Oursler MJ; Khosla S; Monroe DG
J Cell Biochem; 2011 May; 112(5):1392-402. PubMed ID: 21321991
[TBL] [Abstract] [Full Text] [Related]
18. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
Cai Y; Mohseny AB; Karperien M; Hogendoorn PC; Zhou G; Cleton-Jansen AM
J Pathol; 2010 Jan; 220(1):24-33. PubMed ID: 19882675
[TBL] [Abstract] [Full Text] [Related]
19. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors.
Li X; Hoeppner LH; Jensen ED; Gopalakrishnan R; Westendorf JJ
J Cell Biochem; 2009 Oct; 108(2):378-87. PubMed ID: 19585539
[TBL] [Abstract] [Full Text] [Related]
